Compare AbbVie Inc (ABBV) vs American Express Co (AXP) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

AXP trades at $349.58, down 0.68% on the day, with a bullish technical outlook and strong fundamentals. Revenue grew to $72.23B in 2025, with net income of $10.83B and a 15.13% margin. Recent earnings beat expectations in Q1 2026, and analyst consensus targets $376.36. The stock benefits from premium cardholder growth and strategic partnerships.

Outlook remains positive with mid-teens earnings growth potential, though risks include consumer spending sensitivity and competitive pressures. Institutional sentiment is mixed with 38.6% buy ratings. The current price near $350 offers upside to the consensus target, supported by operational cash flow strength and dividend stability.